| Date | Time | Source | Headline | Symbol | Company |
| 09/12/2011 | 7:10AM | Business Wire | Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results... | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 09/12/2011 | 7:00AM | PR Newswire (US) | Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results... | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 09/07/2011 | 4:15PM | PR Newswire (US) | Amylin Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 08/31/2011 | 9:00AM | Zacks | Risk Reward Balances Alkermes - Analyst Blog | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 08/30/2011 | 11:18AM | Zacks | EU Approval for Lilly's Trajenta - Analyst Blog | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 08/19/2011 | 6:28PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 08/17/2011 | 4:33PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 08/11/2011 | 12:42PM | Zacks | FDA Action Date for Amylin's Bydureon - Analyst Blog | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 08/10/2011 | 4:20PM | Business Wire | BYDUREON™ FDA Action Date Set for January 28, 2012 | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 08/10/2011 | 4:15PM | PR Newswire (US) | BYDUREON™ FDA ACTION DATE SET FOR JANUARY 28, 2012 | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 08/08/2011 | 6:10AM | Edgar (US Regulatory) | Quarterly Report (10-Q) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 08/05/2011 | 12:49PM | Zacks | Novo Nordisk Revenues Up - Analyst Blog | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 08/04/2011 | 7:00PM | PR Newswire (US) | Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial R... | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 08/04/2011 | 9:30AM | PR Newswire (US) | The Zacks Analyst Blog Highlights: Alkermes, Johnson & Johnson, Amylin Pharmaceuticals, Eli Lilly and Company and Elan Corpor... | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 08/03/2011 | 12:38PM | Zacks | Revenues Rise at Alkermes - Analyst Blog | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/28/2011 | 4:07PM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/28/2011 | 9:30AM | Dow Jones News | Amylin, Eli Lilly And Alkermes Submit Reply To FDA On Bydureon | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/28/2011 | 8:05AM | Business Wire | BYDUREON™ Reply Submitted to FDA | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/28/2011 | 8:00AM | PR Newswire (US) | BYDUREON™ Reply Submitted to FDA | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/27/2011 | 10:54AM | Zacks | Amylin Loss Narrows on Lower Costs - Analyst Blog | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/26/2011 | 7:51AM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/26/2011 | 7:30AM | PR Newswire (US) | Amylin Pharmaceuticals Reports Second Quarter Financial Results | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/21/2011 | 6:52AM | Zacks | Eli Lilly Misses onEPS, Beats on Sales - Analyst Blog | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/20/2011 | 2:52PM | Zacks | Alkermes' Fiscal 2012 Guidance - Analyst Blog | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/19/2011 | 4:15PM | PR Newswire (US) | Amylin Pharmaceuticals to Webcast Second Quarter Results | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/18/2011 | 4:05PM | Edgar (US Regulatory) | Statement of Ownership (SC 13G) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/18/2011 | 3:19PM | Dow Jones News | Alkermes Sees Sales Growth After Merger With Elan Drug Tech | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/14/2011 | 8:38AM | Zacks | Earnings Preview: Eli Lilly - Analyst Blog | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/13/2011 | 9:30AM | PR Newswire (US) | The Zacks Analyst Blog Highlights: Alkermes, Amylin Pharmaceuticals, Eli Lilly and Company, Liberty Property Trust and Duke Real | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/12/2011 | 1:00PM | Zacks | Alkermes Candidate Disappoints - Analyst Blog | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |